Biomarker-Driven Lung Cancer

Adult patients with&nbsp;<em>ALK</em>-positive, locally advanced or metastatic non&ndash;small cell lung cancer who had not received a prior ALK inhibitor experienced a more than 50% reduction in the risk of&nbsp;disease progression or death with treatment with brigatinib (Alunbrig), compared with&nbsp;the first-line standard of care, crizotinib.

Patients with&nbsp;<em>ROS1</em> fusion&ndash;positive non&ndash;small cell lung cancer had clinically meaningful and durable benefit across multiple doses of repotrectinib (TPX-0005), according to interim findings from the ongoing phase I/II TRIDENT-1 study,&nbsp;presented at the 19th World Conference on Lung Cancer.

Promising efficacy was seen with the novel targeted therapy poziotinib in patients with metastatic, heavily pretreated&nbsp;<em>EGFR&nbsp;</em>and&nbsp;<em>HER2 </em>exon 20 mutant non&ndash;small cell lung cancer, with a best response rate to date of 55%, according to phase II study results presented at the 19th World Conference on Lung Cancer.

Robert C. Doebele, MD, PhD, discusses resistance in patients with ROS1-positive lung cancer.

HER2 mutations have been identified as another oncogenic driver in the growing list of actionable targets in non&ndash;small cell lung cancer. Based on a mounting body of evidence on the impact of HER2 mutations in lung cancer and the growing focus on personalized medicine, the HER2 receptor has gained focus as a potential target for precision medicine treatments for patients with NSCLC.

A Chemoimmunotherapeutic Approach to Nondriver NSCLC

<em>Targeted Oncology</em>, a print and digital resource that offers content and expert opinions on precision medicine in oncology, launched its second &ldquo;Expert Perspective: Virtual Tumor Board&rdquo; on Wednesday, September 12. The Virtual Tumor Board is a video-editorial board discussion that features key opinion leaders from a specific oncological field. This episode will focus on non&ndash;small cell lung cancer.

A&nbsp;supplemental biologics license application for pembrolizumab (Keytruda) has been granted a priority review designation by the FDA for the frontline treatment of patients&nbsp;with locally advanced or metastatic nonsquamous or squamous non&ndash;small cell lung cancer with a PD-L1 expression level of &ge;1% and no <em>EGFR</em> or <em>ALK</em> genomic tumor aberrations.